A Phase I Study of PF-06671008 Immunotherapy in Patients with Advanced Solid Tumors

Full Title

A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06671008 in Patients with Advanced Solid Tumors


In this study, researchers are finding the highest dose of the investigational drug PF-06671008 that can be given safely in patients with advanced solid tumors. PF-06671008 is called “dual-affinity re-targeting” (DART) therapy. It is a special kind of antibody that binds to both a protein on several types of cancer cells called P-cadherin, as well as to immune cells called T cells. PF-06671008 leads to activation of T cells against cancer. PF-06671008 is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have an advanced solid tumor that cannot be successfully treated with another therapy.
  • At least 4 weeks must pass between the completion of prior therapies and entry into the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. James J. Harding at 646-888-4314.